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Voltage-dependent anion channel-1 (VDAC1) is a highly reg-
ulated -barrel membrane protein that mediates transport of
ions and metabolites between the mitochondria and cytosol of
the cell. VDAC1 co-purifies with cholesterol and is functionally
regulated by cholesterol, among other endogenous lipids.
Molecular modeling studies based on NMR observations have
suggested five cholesterol-binding sites in VDAC1, but direct
experimental evidence for these sites is lacking. Here, to deter-
mine the sites of cholesterol binding, we photolabeled purified
mouse VDAC1 (mVDAC1) with photoactivatable cholesterol
analogues and analyzed the photolabeled sites with both top-
downmass spectrometry (MS), and bottom-upMSpairedwith a
clickable, stable isotope-labeled tag, FLI-tag. Using cholesterol
analogues with a diazirine in either the 7 position of the steroid
ring (LKM38) or the aliphatic tail (KK174),wemappedabinding
pocket in mVDAC1 localized to Thr83 and Glu73, respectively.
WhenGlu73 wasmutated to a glutamine, KK174 no longer pho-
tolabeled this residue, but instead labeled the nearby Tyr62
within this same binding pocket. The combination of analytical
strategies employed in this work permits detailed molecular
mapping of a cholesterol-binding site in a protein, including an
orientation of the sterol within the site. Our work raises the
interesting possibility that cholesterol-mediated regulation of
VDAC1 may be facilitated through a specific binding site at the
functionally important Glu73 residue.
Voltage-dependent anion channel-1 (VDAC1)3 is a highly
regulated -barrel membrane protein that mediates transport
of ions and metabolites between the mitochondria and cytosol,
and is implicated in the control of mitochondrial respiration
and apoptosis (1, 2). Among the endogenous factors that alter
VDAC1 function, membrane lipids have been the subject of
several studies (3–8), in part, because of the marked changes
that occur in mitochondrial lipid composition with apoptosis
(9) and neurodegenerative diseases (10). Sterols and anionic
phospholipids affect VDAC selectivity (6), voltage-dependent
gating (3, 7), and oligomerization (4). Furthermore, sterols co-
purify with VDAC from fungi (11) and bovine heart (12), and
are important for the functional reconstitution of purified
VDAC from eukaryotic expression systems (7).
Compared with -helical integral membrane proteins
(IMPs), relatively few structural studies of -barrel IMPs have
delineated binding sites formembrane lipids (13, 14), and this is
particularly true of cholesterol (15–17). Based on a VDAC
NMR study that reported chemical shifts atmultiple residues in
the presence of cholesterol, five cholesterol-binding sites were
recently proposed by molecular modeling (5, 8). Experimental
evidence for the sites of cholesterol interaction in VDAC is
otherwise lacking.
One approach to map lipid-binding sites is photoaffinity
labeling, in which IMPs are covalently labeled with photoacti-
vatable lipid analogues and the sites of interaction are identified
by bottom-up mass spectrometry (MS) (18, 19). In bottom-up
MS, the photolabeled IMP is digested into peptides, and the
photolabeled sites are determined by identifying and sequenc-
ing the associated peptide-ligand adducts. We have found this
process to be particularly challenging for sterol-based ligands
because the resulting peptide adducts have poor aqueous solu-
bility and consistently undergo adduct loss with conventional
collision-induced dissociation fragmentation (20). To over-
come these challenges, we have employed FLI-tag, a clickable
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stable isotope-labeled tag, which enables peptide adducts to be
identified by an MS1 level search (20). We have also utilized
top-down MS to gain complementary information regarding
the efficiency, stoichiometry, and sites of photolabeling. Using
two analogues with a photoactivatable diazirine in different
positions, we have mapped a cholesterol binding pocket with a
preferred ligand orientation in mVDAC1.
Results
Cholesterol analogues photolabel mVDAC1with variable
efficiency and a stoichiometry of one
To determine cholesterol-binding sites in VDAC1, we pho-
tolabeledWTmouse VDAC1 (mVDAC1) with two cholesterol
analogues that have a photoactive diazirine in either the 7-po-
sition (LKM38) (21) or the aliphatic tail (KK174) (see Fig. 1A for
structures and supplemental materials for KK174 synthesis).
These reagents were designed to permitmapping of cholesterol
binding pockets by placing the diazirine in different positions.
They also contain an alkyne allowing for the attachment of FLI-
tag to facilitate identification of peptide-steroid adducts (20).
Top-down MS of photolabeled mVDAC1 was first performed
to characterize the efficiency and stoichiometry of labeling. The
masses of mVDAC1 photolabeled by LKM38 and KK174 are
listed in Table 1. First, mVDAC1 was photolabeled three times
with 100 M of cholesterol analogue added each time. LKM38,
which has the diazirine in the 7-position, photolabeled
mVDAC1 with an efficiency of only 38% (Fig. 1A). KK174,
which has the diazirine in the aliphatic tail, photolabeled
mVDAC1 with 100% efficiency; the absence of a feature corre-
sponding to mVDAC1 photolabeled with two ligands is consis-
tent with a stoichiometry of one (Fig. 1A). HCD fragmentation
of intact mVDAC1 gives limited sequence coverage, and there-
fore top-down mass spectrometry can only localize photo-in-
corporation of the ligands to a general region within the
protein. Fragmentation of photolabeled mVDAC1 showed a
series of b ions that localize the photolabeled site to a region
encompassing residues 44–120 for LKM38, and residues
44–128 for KK174 (Fig. 1B). The variable photolabeling effi-
ciencies of these two analogues under exhaustive photola-
beling conditions suggest that they may photolabel different
residues within this region. We also tested KK174 photola-
beling of mVDAC1 at different concentrations, which dem-
onstrated concentration-dependent labeling that saturates
above 100 M (Fig. 2, A and B). The apparent EC50 of photo-
labeling is 15.3 M (Fig. 2B), which is a function of both
binding and photochemical efficiency and thus not indica-
tive of binding affinity.
LKM38 and KK174 define a cholesterol binding pocket inWT
mVDAC1 by photolabeling Thr83 and Glu73
Todetermine the exact residues photolabeled by LKM38 and
KK174, mVDAC1 was photolabeled with each reagent three
times at 30 and 100M. The photolabeled proteinswere deriva-
tized with FLI-tag using copper-catalyzed cycloaddition. Bot-
tom-upmass spectrometry was performed using an established
protocol (22), and peptide adducts were identified using an
automated pairs search followed by manual interpretation of
the ETD fragmentation spectra. All photolabeled residues are
listed inTable 2.We first examinedKK174.A search of theMS1
data identified multiple paired features consistent with pep-
tide-KK174 adducts (supplemental Table S1). Analysis of the
ETD fragmentation spectra for each of these paired features
localized the site of KK174 insertion to Glu73 (Fig. 3, A and B,
Figure 1. Top-down MS of mVDAC1 photolabeled with cholesterol ana-
logues. A, chemical structures of cholesterol analogues, and associated
deconvoluted spectra of mVDAC1 photolabeled with LKM38 and KK174. For
LKM38, two peaks in the deconvoluted spectrum represent unlabeled and
singly labeledmVDAC1 at 32,157 and 32,553 Da, respectively. For KK174, the
one peak represents singly labeled mVDAC1 at 32,537 Da. B, HCD fragment
ion assignments obtained by isolating the LKM38- and KK174-photolabeled
species, respectively. Amino acids are numbered to exclude the first 12 resi-
dues in the N terminus that comprise the affinity tag. The gray lines represent
b and y ions that do not contain a ligand adduct. The black lines represent b
ions that do contain a ligand adduct and were identified by searching the
fragmentationdata against adatabase inwhich the ligandmasswasadded to
the N-terminal methionine. The absence of red lines indicates an absence of y
ions identified by searching against a database in which the ligandmass was
added to the C-terminal alanine.
Cholesterol-binding sites in VDAC
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supplemental Table S1). No other photolabeled residues were
identified consistent with a stoichiometry of one (supplemental
Table S1).
For LKM38we identified two paired features consistent with
peptide-LKM38 adducts (supplemental Table S1). Both fea-
tures localized the site of LKM38 insertion to Thr83 (Fig. 3, C
and D). Interestingly, Thr83 is directly adjacent to Glu73 in the
neighboring -strand based on the mVDAC1 crystal structure
(23). Despite being in such close proximity to Glu73, LKM38
selectively photolabels Thr83. No peptide adducts with Glu73
labeling were observed in the LKM38 sample (supplemental
Table S1). To further explore whether these two residues form
a single cholesterol-binding site, Autodock simulations were
performed using cholesterol and the mVDAC1 structure (23,
24), with docking constrained to a 30 30-Å area centered on
Glu73. After clustering 1000 poses, the two most populated
clusters show cholesterol bound to a groove formed by Phe71,
Glu73, Thr83, and Ile85 as well as Tyr62 and Ser101 on either end
of the cholesterolmolecule (Fig. 3E). The pose thatmost closely
agreeswith the experimental data shows, quite remarkably, that
the end of the cholesterol aliphatic tail is 3.5 Å from Glu73 and
position 7 of the steroid ring is 2.5 Å from Thr83 (Fig. 3F). In
summary, using two cholesterol analogues with the photo-
activatable diazirine in different positions, we have precisely
mapped a cholesterol-binding site in mVDAC1.
Competitive inhibition of cholesterol photolabeling in
mVDAC1
To confirm that the photolabeled site is an actual cholester-
ol-binding site, we photolabeled mVDAC1 with 1 M KK174
or LKM38 in the presence of excess cholesterol. Photolabeled
mVDAC1was detected by coupling the photolabeled protein to
TAMRA using click chemistry, separating the protein by SDS-
PAGE, and visualizing with fluorescent imaging. Labeling by
KK174 was inhibited by 30 M cholesterol, and labeling by
LKM38 showed a trend toward inhibition that was not statisti-
cally significant (Fig. 4, A and B). Competitive inhibition of
photolabeling by cholesterol for KK174 is consistent with the
conclusion that cholesterol binds to the site photolabeled by
this analogue.
Cholesterol analogues photolabel E73mutants: top-down
analysis
Top-down analysis of photolabeled E73Q and E73AmVDAC1
revealed reduced labeling efficiency in the mutants for both
LKM38 (8% for E73Q and 13% for E73A) and KK174 (21% for
E73Q and 10% for E73A) (Fig. 5,A and B). Moreover, top-down
analysis with HCD fragmentation for both mutants identified
photolabeled sites in two regions, compared with just one for
WT (Fig. 5, C and D). LKM38 photolabeling of E73Q showed a
series of b ions localizing a site or sites from residues 44–135, as
Figure2.Concentration-dependentphotolabelingofmVDAC1byKK174
demonstrates saturation and a stoichiometry of one. A, deconvoluted
spectra of mVDAC1 photolabeled with KK174 at 0, 10, 30, and 200 M. The
theoretical average masses of unlabeled mVDAC1, singly labeled mVDAC1,
and doubly labeledmVDAC1 are 32,154, 32,534, and 32,914 Da, respectively.
B, scatter plot of the photolabeling efficiency of mVDAC1 by KK174. Data are
fit with a four-parameter logistic equation, which yields an apparent EC50 of
15.3 M and Hill slope of 1.6.
Table 1
Masses of photolabeled mVDAC1 acquired on the Elite LTQ
Average mass Theoretical mass Mass accuracy
Da ppm
WT LKM38 32553.0 32550.38 81
WTKK174 32537.0 32534.35 82
E73Q LKM38 32550.0 32549.39 19
E73Q KK174 32537.0 32533.36 112
E73A LKM38 32493.0 32492.34 20
E73A KK174 32477.4 32476.31 34
Table 2
Summary of KK174 and LKM38 photolabeling sites in mVDAC1
100 M 3 30 M
WT KK174 Glu73 Glu73
LKM38 Thr83 None identified
E73Q KK174 Tyr62, Lys110, Tyr173, Asp230, Ala283 Lys110
LKM38 None identified None identified
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well as a series of y ions localizing a site or sites from residues
133–209 (Fig. 5C). A similar pattern of altered HCD fragmen-
tationwas observed forKK174 labeling of E73Q (Fig. 5C) aswell
as KK174 and LKM38 photolabeling of E73A (Fig. 5D). This
suggests that there is at least one additional site of cholesterol
labeling in the E73Q and E73A mutants compared with WT.
KK174 photolabels multiple residues in the E73Qmutant
including Tyr62 in the cholesterol binding pocket
Bottom-up analysis was performed for LKM38 and KK174
photolabeling of E73Q. For KK174, we identified multiple pep-
tide adducts (supplemental Table S1). Three peptide-KK174
adducts were identified in which KK174 insertion was localized
to Tyr62 (Fig. 6, A and B). Interestingly, this residue is adjacent
to Glu73 in themVDAC1 structure. Based on themodeled cho-
lesterol binding pocket, Tyr62 is 6.0 Å away from the flexible
aliphatic tail of cholesterol using the most prominent docking
pose (Fig. 6C). Thus, it appears that cholesterol still binds to a
groove (Fig. 6D) defined by Thr83, Gln73, and Tyr62 in the E73Q
mutant. However, most likely because tyrosine is more nucleo-
philic than glutamine, Tyr62 becomes the preferred target for
KK174 over Gln73. In addition to Tyr62, four other residues
were photolabeled by KK174 in the E73Q mutant: Lys110,
Tyr173, Asp230, and Ala283 (Fig. 7, supplemental Table S1).
KK174 labeling of the lysine residue, Lys110 (Fig. 7,A, B, and E),
is observed with both exhaustive photolabeling (100 M  3)
and photolabeling at 30 M (supplemental Table S1). Labeling
of Tyr173 (Fig. 7,C andD) is consistentwith top-down fragmen-
tation data where photolabeled sites in E73Q were localized to
two regions including a C-terminal region, which was not
Figure 3. Bottom-up MS of mVDAC1 photolabeled with cholesterol analogues maps a cholesterol-binding site. A, representative MS1 doublet corre-
sponding to the peptide GLTFTEKW labeled with KK174 (z 4) and coupled to light and heavy FLI-tag. B, fragmentation (ETD) spectra corresponding to the
heavy feature in A. The site defining ions localize KK174 labeling to Glu73. C, a representative MS1 doublet corresponding to the peptide NTDNTLGTEIT-
VEDQLARGL labeled with LKM38 (z 4) and coupled to light and heavy FLI-tag. D, fragmentation (ETD) spectra corresponding to the light feature in C. Site
defining ions localize LKM38 labeling to Thr83. E, a cholesterol-binding pose from AutoDock bound by Tyr62, Phe71, Glu73, Thr83, Ile85, and Ser101. F, same
cholesterol binding pose as in E showing the aliphatic tail 3.5 Å from Glu73 and the 7 position 2.5 Å from Thr83, consistent with KK174 and LKM38 labeling of
these residues.
Cholesterol-binding sites in VDAC
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detected in WT. Tyr173 is in close proximity to one of the sites
previously identified by molecular modeling (25). We repli-
cated this result by performing an Autodock simulation that
searched the entire mVDAC1 structure, and identified a highly
populated cluster within this site. The average pose of choles-
terol in this site shows the flexible aliphatic tail bound byTrp149
and Val171, but also in close proximity to Tyr173 (8 Å) (Fig.
7F). Due to the low efficiency of LKM38 photolabeling in the
mutants, we were unable to identify LKM38-labeled sites in
E73Q by bottom-up mass spectrometry.
Mixing experiment to test for the formation of a long-lived
reactive intermediate
Aliphatic diazirines are capable of forming short-lived reac-
tive carbenes and also of rearranging to form long-lived inter-
mediates, such as a diazo compound (26). Formation of long-
lived intermediates increase the likelihood of ligand diffusion
and labeling of residues remote from the binding site. To test if
KK174 and LKM38 form long-lived reactive intermediates, we
irradiated 30 M of each reagent for 1 min prior to immediate
mixing with mVDAC1. We then clicked the samples to
TAMRA, separated the protein via SDS-PAGE, and visualized
via fluorescent imaging. Irradiating LKM38 prior to mixing
with mVDAC1 does not result in significant labeling, in con-
trast to KK174 which does (Fig. 8). This indicates that activated
KK174 but not LKM38 forms a long-lived intermediate with a
lifetime of seconds to minutes.
Discussion
Cholesterol is abundant and highly regulated in membranes,
including the outer mitochondrial membrane where VDAC is
the most abundant integral membrane protein (27, 28). The
fact that multiple cholesterol molecules remain bound to
VDAC after detergent solubilization and purification indicates
a specific interaction (11, 12), which is likely mediating effects
such as the modulation of VDAC gating (6, 11). However, the
structural basis of cholesterol interaction with VDAC has not
been well characterized. We utilized a photoaffinity labeling
approach combinedwith top-down andbottom-upMS to iden-
tify andmap cholesterol-binding sites inmVDAC1. Photolabel-
ing efficiency and fragmentation patterns provided by top-
downMS complemented our residue level site identification by
bottom-up MS. Furthermore, derivatization with FLI-tag and
subsequent ETD fragmentation enabled detection of sterol-
based peptide adducts and site-defining ions, which are other-
wise difficult to identify due to collision cell adduct loss (20).
Four key aspects of cholesterol photolabeling in WT
mVDAC1 support the photolabeled residues being a specific
cholesterol-binding site. First, residues photolabeled by two
cholesterol analogues, LKM38 with the diazirine on the 7-po-
sition of the steroid ring, and KK174 with the diazirine on the
aliphatic tail, map a single binding pocket in WT mVDAC1.
Glu73 and Thr83, which are photolabeled by KK174 and
LKM38, respectively, are separated by only 6Å in themVDAC1
crystal structure. KK174 photolabels Glu73 with high efficiency
Figure 4. Competitive inhibition of LKM38 and KK174 photolabeling ofmVDAC1 by cholesterol. SDS-PAGE ofWTmVDAC1 photolabeled for 1minwith
1M LKM38 (A) or KK174 (B) in the absence and presence of 10 or 30M cholesterol. The gel bands on the left show fluorescence signal with TAMRA or SYPRO
Ruby. The scatter plots on the right showdensitometrymeasurements of TAMRA signal from three separate experiments. Error bars indicate S.D. * indicatesp
0.05 and ** p 0.01 based on an analysis of variance with Tukey HSD test.
Cholesterol-binding sites in VDAC
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consistent with the photochemical preference of aliphatic
diazirines for nucleophilic acidic amino acids (26). The fact that
LKM38 labels Thr83, rather than the nearby, more nucleophilic
glutamate residue, indicates that cholesterol is significantly
constrained within this binding pocket.
A second aspect of cholesterol photolabeling that argues for
specific binding is the photolabeling of E73Q mVDAC1. The
conservative E73Qmutation abolishes KK174 photolabeling of
residue 73, without disrupting binding at this site because
KK174 then photolabels the nearby residue, Tyr62. With the
diazirine at the end of a flexible aliphatic tail, we predict that
KK174 photolabels Tyr62 within the constraints of the same
binding pocket defined in WT mVDAC1. The orientation of
cholesterol within this binding pocket agrees remarkably well
with results from docking simulations.
Third, KK174 photolabels mVDAC1 with a stoichiometry
of one at concentrations well above saturation (i.e. 100%
mVDAC1 is photolabeled), indicating that this singular photo-
labeled site is highly specific. Even at concentrations greater
than three times needed to saturate labeling at Glu73, a
mVDAC1 species labeled with two KK174 is not observed by
top-downMS. This finding is particularly remarkable in light of
the fact that KK174 forms a long-lived reactive intermediate,
which may be prone to diffuse and nonspecifically photolabel
other sites.
Last, inhibition of KK174 photolabeling inWTmVDAC1 by
excess cholesterol also argues for Glu73 being a cholesterol-
binding site. Cholesterol inhibition of LKM38 photolabeling
wasmodest and not statistically significant.We have found that
competitive inhibition of ligand photolabeling also cannot be
Figure 5. Top-downMS of E73Q and E73AmVDAC1 photolabeledwith cholesterol analogues. A, deconvoluted spectra of E73QmVDAC1 photolabeled
with LKM38 andKK174. For LKM38, the twopeaks represent unlabeled and singly labeled E73Qat 32,153 and32,550Da, respectively. For KK174, the twopeaks
represent unlabeled and singly labeled E73Q at 32,153 and 32,493 Da, respectively. B, same as A for E73A mVDAC1. For LKM38, the two peaks represent
unlabeled and singly labeled E73A at 32,097 and 32,493 Da, respectively. For KK174, the two peaks represent unlabeled and singly labeled E73A at 32,097 and
32,477Da, respectively.C, HCD fragment ion assignments obtainedby isolating the LKM38- andKK174-E73Qphotolabeled species, respectively. The gray lines
representb and y ions that donot contain a ligandadduct. Theblack lines representb ions that contain ligandadduct identifiedby searchingagainst adatabase
in which the ligand mass was added to the N-terminal methionine. The red lines represent y ions that contain ligand adduct identified by searching against a
database in which the ligand mass was added to the C-terminal alanine. D, same as C for E73A mVDAC1.
Cholesterol-binding sites in VDAC
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demonstrated for known ligand-receptor interactions such as
the GABA receptor and neurosteroids (19). We suspect the
reasons competition is difficult to demonstrate or replicate in
certain cases include the low affinity of ligands such as neuros-
teroids or cholesterol, the irreversible nature of photolabeling
combinedwith relatively long photolabeling times, and the pos-
sibility that photoactivatable analogues have different binding
affinities than the ligands themselves (29). Thus, whereas the
presence of inhibition by cholesterol of KK174 photolabeling
confirms that Glu73 is a cholesterol-binding site, the lack of
significant inhibition in the case of LKM38 does not lead to the
opposite conclusion.
Glu73 is a uniquely positioned, charged amino acid in the
transmembrane region of -strand 4 that faces out into the
membrane. Interestingly, this residue is an important determi-
nant ofVDAC1channel activity and is implicated in hexokinase
or ruthenium red-mediated inhibition of apoptosis (30). The
presence of a cholesterol-binding site at Glu73 raises the inter-
esting hypothesis that this site is mediating the effects of cho-
lesterol on VDAC function (6, 11). Cholesterol binding at Glu73
may also bemediating interactionswith other proteins, because
Glu73 is critical for the interaction of hexokinase-I with VDAC
(30) and potentially dimerization of VDAC itself (23).
We also observed that cholesterol analogues photolabel
additional sites in E73Q compared with WT mVDAC1. Evi-
dence for specific binding of cholesterol to these residues is
limited. One site, Tyr173, is near one of five binding sites previ-
ously predicted by molecular modeling (8). Unfortunately, low
photolabeling efficiency prevented the mapping of these sites
using LKM38 in the E73Q mutant. Given the finding that
KK174 can form a long-lived reactive intermediate, we cannot
exclude the possibility that labeling of these residues is nonspe-
cific, resulting from diffusion of a long-lived reactive interme-
diate. This is especially likely for Asp230, which is located in a
soluble loop of the mVDAC1 protein.
We also cannot exclude the possibility that there are choles-
terol sites not identified by our photolabeling experiments. Five
cholesterol molecules were estimated to bind VDAC when
purified frombovine heart (12). A previousmolecularmodeling
study defined five cholesterol-binding sites based on the
mVDAC1 structure and chemical shift data from an NMR
study (5, 8). We recognize that our cholesterol analogues
mainly photolabel nucleophilic residues and that the sites pro-
posed in the computation study are predominantly composed
of aliphatic amino acids and few hydrophilic residues. Thus,
these other putative cholesterol-binding sites might not have
been identified due to limitations in our photolabeling reagents.
Alternatively, molecular docking to a staticmVDAC1 structure
or NMR data obtained in detergent micelles may not recapitu-
late the dynamic state of mVDAC1 in a membrane environ-
ment, where the cholesterol binding pocket we identified at
Glu73 is predicted to have significant flexibility (31). Indeed,
photoaffinity labeling provides an advantage over studies based
on static crystal structures in that multiple protein conforma-
tions are likely sampled in a lipid environment.
In conclusion, we have identified a specific cholesterol-bind-
ing site in mVDAC1 using photoaffinity labeling. Using two
cholesterol analogues with the diazirine in different positions,
we have precisely mapped this site with photolabeling of Glu73,
Thr83, and Tyr62. This work raises the interesting hypothesis
that cholesterol regulation of VDAC1 may be mediated
through a specific binding site at this functionally important
Figure 6. Photolabeling a third residue, Tyr62, in the cholesterol binding pocket in E73Q mVDAC1. A, an MS1 doublet corresponding to the peptide
TSSGSANTETTKVNGSLETKYRWTEY fromE73QmVDAC1photolabeledwithKK174 (z5) and coupled to light andheavy FLI-tag.B, fragmentation (ETD) spectra
corresponding to the feature in A. Site defining ions localize KK174 photolabeling to Tyr62. C, the same cholesterol binding pose as in Fig. 2E showing Tyr62,
Glu73, and Thr83. D, space filling view of the binding pocket mapped by KK174 and LKM38.
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Figure 8. Formation of a long-lived reactive intermediate for KK174 but not LKM38. SDS-PAGE of mVDAC1 photolabeled with 30M KK174 and LKM38.
KK174 and LKM38wereUV irradiated for 1min in the presence ofmVDAC1 (UV Ligand Protein), or in the absence ofmVDAC1 followedby immediatemixing
with mVDAC1 (UV Ligand). The gel bands show fluorescence signal with TAMRA (left) or SYPRO Ruby (right).
Figure 7. Additional sites of KK174 photolabeling in E73QmVDAC1. A, anMS1 doublet corresponding to the peptide TGKKNAKIKTGY labeledwith KK174
(z4) and coupled to light andheavy FLI-tag.B, fragmentation (ETD) spectra corresponding to theheavy feature inA. Site defining ions localize KK174 labeling
to Lys110. C, an MS1 doublet corresponding to the peptide AVGYKTDEF labeled with KK174 (z 4) and coupled to light and heavy FLI-tag. D, fragmentation
(ETD) spectra corresponding to the light feature in C. Site defining ions localize KK174 labeling to Tyr173. E, mVDAC1 crystal structure (PDB code 3emn)
highlighting thephotolabeled residue Lys110. F, a cholesterol bindingpose fromAutodock locatedwithin apreviously identified cholesterol bindingpocket (8)
formedbyVal171, Ala151, Leu144, Ile123, Tyr146, and Trp149. The aliphatic tail of cholesterol in this pose is near Tyr173, consistentwith KK174 labelingof this residue
in E73QmVDAC1.
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residue. To our knowledge, this is the first time a sterol-binding
site has been defined with photolabeling reagents in such
molecular detail. This approach could be applied to precisely
map sterol-binding sites in other integral membrane proteins.
Experimental procedures
Expression and purification ofmVDAC1 from Escherichia coli
Protein expression and purification were performed as
described previously (23). In short, mVDAC1 carrying a His6
tag was expressed usingM15 E. coli cells. Inclusion bodies were
isolated, solubilized, and mVDAC1 was purified on a Talon
affinity column. The protein was then refolded and a size exclu-
sion chromatography step allowed isolation of a homogeneous
population.
Top-downMS of photolabeledmVDAC1
Reconstitution of mVDAC1, photolabeling, and top-down
MS was performed as previously described (32–35). 120 g of
WT or mutant mVDAC1 was reconstituted by adding a 35%
solution of L- -dimyristoylphosphatidylcholine/CHAPSO
bicelles in a 4:1 volume ratio of protein to bicelles and incubat-
ing on ice for 30 min. Samples were then diluted to 100 l with
20 mM Tris buffer, pH 8, and photolabeled with cholesterol
analogues at different concentrations via irradiation in a quartz
cuvette with320 nmUV light as previously described (35). 30
g were removed for bottom-up analysis. The samples were
then reduced with 250 mM DTT as previously described (36).
Briefly, methanol, chloroform, and water in approximately
equal volumes were added to the sample, vortexed, and centri-
fuged. The upper phase was removed and methanol and water
were added and centrifuged three more times to further wash
the sample. After the final wash, the precipitated protein was
pelleted, reconstituted in 2l of 90% formic acid (37), and then
diluted in 120 l of chloroform/methanol/water (4:4:1). Top-
down MS analysis was performed by direct injection of this
sample at 3 l/min using a Max Ion API source with a HESI-II
probe into an Orbitrap Elite MS (Thermo Scientific, Waltham,
MA). Full spectra of intact photolabeled mVDAC1 were
acquired on the LTQ using a spray voltage of 4 kV, capillary
temperature of 320 °C, in source dissociation voltage of 30 V,
and otherwise standard tune parameters. The HCD/C-trap P
was adjusted to between 0.05 and 0.1 to optimizeOrbitrap anal-
ysis of fragmentation spectra. HCD fragmentation spectra were
acquired at 60,000 resolution, with an AGC target of 5  105,
normalized energy of 10, activation time of 0.1 ms, and 4 m/z
isolationwindow of the 31 charge state. Deconvolution of full
spectra from the LTQ was performed using MagTran (38).
MASH was used for deconvolution of isotopically-resolved
spectra to obtain monoisotopic masses, and to analyze top-
down HCD fragmentation data (39). Fragment ions were
searched using amass accuracy of 1.1 Da to account for the “ 1
Da” error (33). Fragment ions containing ligand were identified
by adding the monoisotopic mass of the ligand to the N-termi-
nal or C-terminal amino acids and searching for fragment ions
plus ligand. Each identified fragment ion was manually verified
and accepted if within 10 ppm. Fit of the concentration depen-
dence of KK174 photolabeling efficiency was performed in
Excel using a standard logistic binding equation,
y  min
max	min
1  xEC50
	Hill slope (Eq. 1)
where max is maximum labeling efficiency set at 100%, min is
minimum labeling efficiency set at 0%.
Click chemistry and endoproteolytic digestion of photolabeled
mVDAC1
Aliquots of photolabeled VDAC were diluted to 100 l and
SDSwas added to 1%. FLI-tag was covalently attached at sites of
ligand incorporation via copper-catalyzed cyclo-addition
(click chemistry) as previously described (40). Briefly, 2 mM
C6H7NaO6, 0.1 mM Tris(benzyltriazolylmethyl)amine, and 1
mMCuSO4were added and the reactionwas initiated by 0.5mM
FLI-tag (in a 1:1 light to heavy ratio). The reaction was kept at
room temperature overnight. As previously described (22), the
protein was precipitated with a 2D SDS clean-up kit (GE
Healthcare) and delipidated with 5% RapigestTM (in 20 l of
100 mM Tris, pH 8.0, 8 M urea) at 37 °C for 1 h. The protein was
precipitated a second time and resuspended in 8 M urea, 0.2%
RapigestTM. The protein was then reduced with 5 mM triscar-
boxyethylphosphine, alkylated with 5 mM idoacetamide, and
alkylation was quenched with 5 mM DTT. The protein was
digested overnight at 37 °Cwith 2g of endoprotease LysC, and
then diluted to 1 M urea with 100 mM Tris, pH 8.0,  10 mM
CaCl2 and digested with 2 g of chymotrypsin for 3 or 6 h.
Digestions were stopped with 1% formic acid (FA) and incu-
bated at 37 °C for 30 min before peptides were sequentially
extractedwithC4 andC18 stage tips. Peptideswere eluted from
stage tips with 10% ACN, 1% FA, dried via vacuum centrifuga-
tion, resuspended in 10% ACN, 1% FA, and analyzed by
LC/MS/MS on an Orbitrap Elite mass spectrometer.
Liquid chromatography and high resolution tandemmass
spectrometry
Samples were analyzed as previously described (20). Samples
were separated on a homepackedC18 column (15 cm 75M
200 Å) and introduced to the mass spectrometer with a nano-
spray source. Samples were separated on a 102-min gradient (5
min hold at 10%ACN, 1%FA, increase to 90%ACN, 1%FAover
85 min, hold at 90% ACN, 1% FA, flow rate  800 nl/min).
Survey scans were collected in the Orbitrap (res 60,000) and
MS2 (MS/MS) scans were acquired using data-dependent
acquisition of the 20most abundant features.MS2 spectra were
acquired using either collision-induced dissociation (normal-
ized collision energy  35) or ETD (100 ms activation time).
Dynamic exclusion limitedMS2 collection of a givenm/z to one
event every 15 s. ETD MS2 collection was limited to features
with z 3.
MS1-based pair search
Bottom-up spectra were analyzed via a pair search as previ-
ously described (20). Briefly, .raw data were converted to .mzml
via MSConvert. OpenMS featurefinder multiplex tool was
used to identify pairs separated by 10.008 Da and results
were processed in Knime to exclude pairs with integral of
intensity differences greater than 50%. The feature list cre-
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ated in Knime was exported to Excel and z   2 pairs were
manually analyzed in Xcalibur for correct charge state and
isotope distribution.
MS2-based software searches
ETD fragmentation spectra were searched against a database
containing the mVDAC1 sequence (UniProtKB code Q60932)
modified with a His6 tag and filtered at a 1% false discovery rate
using PEAKS 8.0 (Bioinformatics Solution Inc.). Met oxidation
and Cys carbamidomethylation were included in each sample
as variable modifications. Customized modifications were cre-
ated for the add weight of KK174  FLI-tag (light m/z 
680.474, heavy m/z  690.482) and LKM38  FLI-tag (light
m/z 696.505, heavym/z 706.513).
Gel-based competition assay
mVDAC1was photolabeled for 1min with 1M LKM38 and
KK174 in the absence or presence of 10 or 30 M cholesterol.
Samples were clicked to TAMRA azide (Thermo Fisher Scien-
tific) by mixing the samples with 2 mM sodium ascorbate, 0.1
mM Tris(benzyltriazolylmethyl)amine, and 1 mM copper sul-
fate, followed by 100 M TAMRA azide. The reaction pro-
ceeded overnight at room temperature. The samples were then
run on a 12% Tris glycine gel and imaged using a Typhon FLA
9500 scanner (GE Healthcare) set for TAMRA fluorescence
(550/580 nm excitation/emission). The gels were then stained
overnight for SYPRO Ruby imaging. Densitometry was per-
formed using ImageJ and statistical analysis was performed
using analysis of variance with a Tukey HSD test.
Mixing experiment
30MKK174 and LKM38 were irradiated with UV for 1 min
in the presence or absence of mVDAC1. Reagent irradiated in
the absence of mVDAC1 was immediately mixed with pro-
tein following UV irradiation. All samples were then incu-
bated in the dark for 5 min before being denatured with SDS
and clicked to TAMRA azide. SDS-PAGE, TAMRA fluores-
cence imaging, and SYPRO Ruby imaging were performed as
described above.
Autodock analysis of the cholesterol-binding site
Cholesterol binding poses were obtained with AutoDock 4.2
(24). Docking was performed with the mVDAC1 crystal struc-
ture (PDB code 3emn) prepared in AutoDock Tools by deleting
waters, adding hydrogen, computing Gasteiger charges, and
merging non-polar hydrogens. The cholesterol ligand was pre-
pared by converting an sdf file from Pubchem into a pdb file
using Open Babel (41), and partial charges and torsion angles
were calculated using PRODRG set for reduced charges and
energy minimization (42). The AutoDock grid box was chosen
to be a 30  30  30-Å space entered on Glu73 with 0.3-Å
spacing. Alternatively, docking was also performed with a grid
that encompassed the entire protein with 1.0-Å spacing. Dock-
ing was performed using the genetic algorithm, 1000 runs, and
otherwise default parameters. Clustering of the resulting 1000
poses at 2-Å root mean square deviation yielded multiple clus-
ters, which were considered for comparison with photolabeled
data.
Author contributions—W.W. C. and M. M. B. contributed to the
conception, design, acquisition, and analysis of data, and writing of
manuscript. A. S. E. contributed to the conception, design, and writ-
ing of manuscript. L. B. and J. A. purified mVDAC1 and edited the
manuscript. J. P. W. and Z. C. contributed to the analysis and inter-
pretation of data. D. F. C., L. M. M., and K. K. contributed to the
synthesis of cholesterol analogues. J. W. J. assisted in the synthesis of
FLI-tag. All authors reviewed and approved the content of the final
manuscript.
Acknowledgment—We thank Sunjoo Lee for assistance in setting up
Autodock simulations.
References
1. McCommis, K. S., and Baines, C. P. (2012) The role of VDAC in cell death:
friend or foe? Biochim. Biophys. Acta 1818, 1444–1450
2. Colombini, M. (2012) VDAC structure, selectivity, and dynamics.
Biochim. Biophys. Acta 1818, 1457–1465
3. Rostovtseva, T. K., Kazemi, N., Weinrich, M., and Bezrukov, S. M. (2006)
Voltage gating of VDAC is regulated by nonlamellar lipids of mitochon-
drial membranes. J. Biol. Chem. 281, 37496–37506
4. Betaneli, V., Petrov, E. P., and Schwille, P. (2012) The role of lipids in
VDAC oligomerization. Biophys. J. 102, 523–531
5. Hiller, S., Garces, R. G., Malia, T. J., Orekhov, V. Y., Colombini, M., and
Wagner, G. (2008) Solution structure of the integral human membrane
protein VDAC-1 in detergent micelles. Science 321, 1206–1210
6. Mlayeh, L., Chatkaew, S., Le´onetti, M., andHomble´, F. (2010)Modulation
of plant mitochondrial VDAC by phytosterols. Biophys. J. 99, 2097–2106
7. Popp, B., Schmid, A., and Benz, R. (1995) Role of sterols in the functional
reconstitution of water-soluble mitochondrial porins from different or-
ganisms. Biochemistry 34, 3352–3361
8. Weiser, B. P., Salari, R., Eckenhoff, R. G., and Brannigan, G. (2014) Com-
putational investigation of cholesterol binding sites on mitochondrial
VDAC. J. Phys. Chem. B 118, 9852–9860
9. Crimi, M., and Esposti, M. D. (2011) Apoptosis-induced changes in mito-
chondrial lipids. Biochim. Biophys. Acta 1813, 551–557
10. Aufschnaiter, A., Kohler, V., Diessl, J., Peselj, C., Carmona-Gutierrez, D.,
Keller, W., and Bu¨ttner, S. (2017) Mitochondrial lipids in neurodegenera-
tion. Cell Tissue Res. 367, 125–140
11. Freitag, H., Neupert, W., and Benz, R. (1982) Purification and characteri-
sation of a pore protein of the outer mitochondrial membrane fromNeu-
rospora crassa. Eur. J. Biochem. 123, 629–636
12. De Pinto, V., Benz, R., and Palmieri, F. (1989) Interaction of non-classical
detergents with the mitochondrial porin: a new purification procedure
and characterization of the pore-forming unit. Eur. J. Biochem. 183,
179–187
13. Lee, A. G. (2003) Lipid–protein interactions in biological membranes: a
structural perspective. Biochim. Biophys. Acta 1612, 1–40
14. Galdiero, S., Galdiero, M., and Pedone, C. (2007) -Barrel membrane
bacterial proteins: structure, function, assembly and interaction with lip-
ids. Curr. Protein Pept. Sci. 8, 63–82
15. Hanson, M. A., Cherezov, V., Griffith, M. T., Roth, C. B., Jaakola, V. P.,
Chien, E. Y., Velasquez, J., Kuhn, P., and Stevens, R. C. (2008) A specific
cholesterol binding site is established by the 2.8-Å structure of the human
2-adrenergic receptor. Structure 16, 897–905
16. Shinoda, T., Ogawa, H., Cornelius, F., and Toyoshima, C. (2009) Crystal
structure of the sodium-potassium pump at 2.4-Å resolution.Nature 459,
446–450
17. Ruprecht, J. J., Mielke, T., Vogel, R., Villa, C., and Schertler, G. F. (2004)
Electron crystallography reveals the structure of metarhodopsin I. EMBO
J. 23, 3609–3620
18. Xia, Y., and Peng, L. (2013) Photoactivatable lipid probes for studying
biomembranes by photoaffinity labeling. Chem. Rev. 113, 7880–7929
19. Chen, Z. W., Manion, B., Townsend, R. R., Reichert, D. E., Covey, D. F.,
Steinbach, J. H., Sieghart, W., Fuchs, K., and Evers, A. S. (2012) Neuros-
Cholesterol-binding sites in VDAC
J. Biol. Chem. (2017) 292(22) 9294–9304 9303
 at W
ashington U
niversity on July 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
teroid analog photolabeling of a site in the third transmembrane domain
of the3 subunit of theGABA(A) receptor.Mol. Pharmacol. 82, 408–419
20. Budelier, M. M., Cheng, W. W., Bergdoll, L., Chen, Z. W., Abramson, J.,
Krishnan, K., Qian, M., Covey, D. F., Janetka, J. W., and Evers, A. S. (2017)
Click chemistry reagent for identification of sites of covalent ligand incor-
poration in integral membrane proteins. Anal. Chem. 89, 2636–2644
21. Castellano, B. M., Thelen, A. M., Moldavski, O., Feltes, M., van derWelle,
R. E., Mydock-McGrane, L., Jiang, X., van Eijkeren, R. J., Davis, O. B.,
Louie, S. M., Perera, R. M., Covey, D. F., Nomura, D. K., Ory, D. S., and
Zoncu, R. (2017) Lysosomal cholesterol activates mTORC1 via an
SLC38A9-Niemann-Pick C1 signaling complex. Science 355, 1306–1311
22. Chen, Z. W., Fuchs, K., Sieghart, W., Townsend, R. R., and Evers, A. S.
(2012) Deep amino acid sequencing of native brain GABAA receptors
using high-resolution mass spectrometry. Mol. Cell. Proteomics 11,
M111.011445
23. Ujwal, R., Cascio, D., Colletier, J. P., Faham, S., Zhang, J., Toro, L., Ping, P.,
and Abramson, J. (2008) The crystal structure of mouse VDAC1 at 2.3-Å
resolution reveals mechanistic insights into metabolite gating. Proc. Natl.
Acad. Sci. U.S.A. 105, 17742–17747
24. Morris, G.M., Huey, R., Lindstrom,W., Sanner,M. F., Belew, R. K., Good-
sell, D. S., and Olson, A. J. (2009) AutoDock4 and AutoDockTools4: au-
tomated docking with selective receptor flexibility. J. Comput. Chem. 30,
2785–2791
25. Weiser, B. P., Woll, K. A., Dailey, W. P., and Eckenhoff, R. G. (2014)
Mechanisms revealed through general anesthetic photolabeling. Curr.
Anesthesiol. Rep. 4, 57–66
26. Das, J. (2011) Aliphatic diazirines as photoaffinity probes for proteins:
recent developments. Chem. Rev. 111, 4405–4417
27. Hallermayer, G., and Neupert,W. (1974) Lipid composition of mitochon-
drial outer and inner membranes of Neurospora crassa. Hoppe-Seyler’s Z.
Physiol. Chem. 355, 279–288
28. Parsons, D. F., and Yano, Y. (1967) The cholesterol content of the outer
and innermembranes of guinea-pig livermitochondria. Biochim. Biophys.
Acta 135, 362–364
29. Woll, K. A., Dailey, W. P., Brannigan, G., and Eckenhoff, R. G. (2016)
Shedding light on anesthetic mechanisms: application of photoaffinity
ligands. Anesth. Analg. 123, 1253–1262
30. Zaid, H., Abu-Hamad, S., Israelson, A., Nathan, I., and Shoshan-Barmatz,
V. (2005) The voltage-dependent anion channel-1 modulates apoptotic
cell death. Cell Death Differ. 12, 751–760
31. Villinger, S., Briones, R., Giller, K., Zachariae, U., Lange, A., deGroot, B. L.,
Griesinger, C., Becker, S., and Zweckstetter, M. (2010) Functional dynam-
ics in the voltage-dependent anion channel. Proc. Natl. Acad. Sci. U.S.A.
107, 22546–22551
32. Whitelegge, J., Halgand, F., Souda, P., and Zabrouskov, V. (2006) Top-
downmass spectrometry of integral membrane proteins. Expert Rev. Pro-
teomics 3, 585–596
33. Ryan, C.M., Souda, P., Bassilian, S., Ujwal, R., Zhang, J., Abramson, J., Ping,
P., Durazo, A., Bowie, J. U., Hasan, S. S., Baniulis, D., Cramer,W. A., Faull,
K. F., and Whitelegge, J. P. (2010) Post-translational modifications of in-
tegral membrane proteins resolved by top-down Fourier transform mass
spectrometry with collisionally activated dissociation.Mol. Cell. Proteom-
ics 9, 791–803
34. Ujwal, R., and Abramson, J. (2012) High-throughput crystallization of
membrane proteins using the lipidic bicelle method. J. Vis. Exp. 59, e3383
35. Darbandi-Tonkabon, R., Hastings, W. R., Zeng, C. M., Akk, G., Manion,
B.D., Bracamontes, J. R., Steinbach, J. H.,Mennerick, S. J., Covey,D. F., and
Evers, A. S. (2003) Photoaffinity labeling with a neuroactive steroid ana-
logue: 6-azi-pregnanolone labels voltage-dependent anion channel-1 in
rat brain. J. Biol. Chem. 278, 13196–13206
36. Wessel, D., and Flu¨gge, U. I. (1984) Amethod for the quantitative recovery
of protein in dilute solution in the presence of detergents and lipids.Anal.
Biochem. 138, 141–143
37. Whitelegge, J. P., Gundersen, C. B., and Faull, K. F. (1998) Electrospray-
ionization mass spectrometry of intact intrinsic membrane proteins. Pro-
tein Sci. 7, 1423–1430
38. Zhang, Z., and Marshall, A. G. (1998) A universal algorithm for fast and
automated charge state deconvolution of electrospray mass-to-charge ra-
tio spectra. J. Am. Soc. Mass Spectrom. 9, 225–233
39. Guner, H., Close, P. L., Cai, W., Zhang, H., Peng, Y., Gregorich, Z. R., and
Ge, Y. (2014)MASH Suite: a user-friendly and versatile software interface
for high-resolution mass spectrometry data interpretation and visualiza-
tion. J. Am. Soc. Mass Spectrom. 25, 464–470
40. Rostovtsev, V. V., Green, L. G., Fokin, V. V., and Sharpless, K. B. (2002) A
stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselec-
tive “ligation” of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl.
41, 2596–2599
41. O’Boyle, N. M., Banck, M., James, C. A., Morley, C., Vandermeersch, T.,
and Hutchison, G. R. (2011) Open Babel: an open chemical toolbox.
J. Cheminform. 3, 33
42. Schu¨ttelkopf, A. W., and van Aalten, D. M. (2004) PRODRG: a tool for
high-throughput crystallography of protein-ligand complexes. Acta Crys-
tallogr. D Biol. Crystallogr. 60, 1355–1363
Cholesterol-binding sites in VDAC
9304 J. Biol. Chem. (2017) 292(22) 9294–9304
 at W
ashington U
niversity on July 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Covey, Julian P. Whitelegge and Alex S. Evers
Janetka, Jeff Abramson, Kathiresan Krishnan, Laurel Mydock-McGrane, Douglas F. 
Melissa M. Budelier, Wayland W. L. Cheng, Lucie Bergdoll, Zi-Wei Chen, James W.
cholesterol-binding site in voltage-dependent anion channel-1
Photoaffinity labeling with cholesterol analogues precisely maps a
doi: 10.1074/jbc.M116.773069 originally published online April 10, 2017
2017, 292:9294-9304.J. Biol. Chem. 
  
 10.1074/jbc.M116.773069Access the most updated version of this article at doi: 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
Supplemental material:
  
 http://www.jbc.org/content/suppl/2017/04/10/M116.773069.DC1
  
 http://www.jbc.org/content/292/22/9294.full.html#ref-list-1
This article cites 42 references, 10 of which can be accessed free at
 at W
ashington U
niversity on July 29, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
